[Effect of irbesartan--angiotensin II type I receptor inhibitor on oxidative metabolism of lipids in essential hypertension].
We evaluated the alters in plasma vasoconstriction eicosanoids (LTC4, TXB2) and diene conjugates (DC) levels in patients with essential hypertension (EH) after chronic (30 days, 235 mg per day) of irbezartane (inhibitor of ANG II type 1 receptor with prolongation action "Aprovel" from "Sanofi") oral administration. Patients with EH have significantly higher plasma both LTC4, TXB2 and DC levels then healthy controls. This imbalance can be beneficially modulated by chronic irbezartane ("Aprovel") administration. It is concluded that ANG II type 1 receptors can be involved in regulation of free arachidomc acid oxidation.
Svishchenko
Ie P
IeP
M.D. Strazhesko Institute of Cardiology, Academy of Medical Science of Ukraine.
Kotsiuruba
A V
AV
Mehed'
O F
OF
Bukhanevich
O M
OM
Radchenko
V V
VV
Hula
N M
NM
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D000077405:Irbesartan; D015227:Lipid Peroxidation / Q000187:drug effects*; D008054:Lipid Peroxides / Q000097:blood; D018384:Oxidative Stress / Q000187:drug effects; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D008054:Lipid Peroxides; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D000077405:Irbesartan